Delhi HC: Non-Proof of Hearing Notice Dispatch Doesn’t by Itself Show no Personal Hearing Was Given  ||  Delhi High Court: No Construction or Residence Allowed on Yamuna Floodplains, Even For Graveyards  ||  J&K High Court: Right to Speedy Trial Includes Appeals; Closes 46-Year-Old Criminal Case Due to Delay  ||  J&K High Court: Courts Must Not Halt Corruption Probes, Refuses to Quash FIR  ||  J&K&L HC: Matrimonial Remedies May Overlap, But Cruelty Claims Cannot be Selectively Invoked  ||  Delhi High Court: Customs Officials Acting Officially Cannot be Cross-Examined as of Right  ||  J&K&L HC: Second Arbitral Reference is Maintainable if Award is Set Aside Without Deciding Merits  ||  J&K&L HC: Gold Voluntarily Given to Customer is 'Entrustment'; Theft Excluded from Insurance Cover  ||  Delhi HC: Working Mothers Cannot be Forced to Bear Full Childcare Burden While Fathers Evade Duty  ||  J&K&L HC: Arbitral Tribunal Not a “Court”; Giving False Evidence Before it Doesn’t Attract S.195 CrPC    

Commerce Minister releases study report on Indian pharma exports to China- (Press Information Bureau) (18 Jun 2018)

MANU/PIBU/0962/2018

Commercial

For India to make a strong pitch for pharma exports to China, the Department of Commerce in coordination with Embassy of India at Beijing commissioned a study on "Enhancing Indian Exports of Pharmaceutical products to China" under the Market Access Initiative Scheme (MAI) to have a proper understanding of Chinese market and to help the Indian pharma industry to evolve appropriate and focused strategy for entry of the Indian generic drugs.

The study examines the health care market, pharmaceutical market the distribution system, procurement and bidding process and the regulatory landscape in China. The study also gives recommendations on how to access the Chinese market.

China' s health-care sector continues to grow rapidly with spending projected to grow from $ 357 billion in 2011 to $ 1 trillion in 2020. From pharmaceuticals to medical products to consumer health, China remains among the world's most attractive markets, and by far the fastest-growing of all the large emerging ones.

The study has been done by IMS Health team which worked with PHARMEXCIL and Industry stakeholders.

Tags : CHINA   PHARMA   EXPORT  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved